Inovio Pharmaceuticals (INO) Share-based Compensation (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Share-based Compensation of $698744.0 for Q1 2026, down 8.61% sequentially from $764561.0 in Q4 2025, and down 50.07% YoY from $1.4 million in Q1 2025.
Inovio Pharmaceuticals (INO) Share-based Compensation (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $698744.0 in Q1 2026.
- Quarterly Share-based Compensation fell 50.07% year-over-year to $698744.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 46.35% YoY) and the FY2025 annual result came in at $3.8 million, down 43.05% from the prior year.
- Share-based Compensation retreated to $698744.0 in Q1 2026 per INO's latest filing, from $764561.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $8.8 million in Q2 2022 and troughed at -$19.3 million in Q4 2022.
- A 5-year average of $627305.6 and a median of $698744.0 in 2026 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 318.12% in 2022, then soared 111.75% in 2023.
- Over 5 years, Share-based Compensation stood at -$19.3 million in 2022, then surged by 111.75% to $2.3 million in 2023, then sank by 41.94% to $1.3 million in 2024, then slumped by 41.89% to $764561.0 in 2025, then fell by 8.61% to $698744.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $698744.0, $764561.0, and $19000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | - |
| 10 | Inovio Pharmaceuticals | 96.72 Mn | 96.72 Mn | - | 753,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 753,000.00 |
| Jun 30, 2026 | 753,000.00 |
| Mar 31, 2026 | 698,744.00 |
| Mar 31, 2026 | 698,744.00 |
| Dec 31, 2025 | 764,561.00 |
| Dec 31, 2025 | 764,561.00 |
| Sep 30, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 40,000.00 |
| Sep 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2024 | 2.53 Mn |
| Mar 31, 2024 | 2.53 Mn |